35 completed, 8 terminated, 4 active not recruiting, 3 unknown. 19 Phase 1, 15 Phase 2, 13 Phase 3, 2 Not applicable.
Follow Brenner Tumor: new trials by email Literature Review of Brenner Tumor trials Research Report on Brenner Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-09-10 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Celgene | 297 | 2012-10-31 | 2019-09-26 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 | |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin belinostat, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2009-12-01 | 2019-07-23 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
Showing 20 of 51. Sign in to see all of them.
Fallopian Tube Neoplasms (38) · Ovarian Neoplasms (37) · Carcinoma, Ovarian Epithelial (27) · Mesothelioma, Malignant (4) · Uterine Cervical Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Pancreatic Neoplasms (3) · Salivary Gland Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Neurotoxicity Syndromes (2)
Adnexal Diseases (51) · Endocrine System Diseases (51) · Female Urogenital Diseases (51) · Female Urogenital Diseases and Pregnancy Complications (51) · Genital Diseases (51) · Genital Diseases, Female (51) · Genital Neoplasms, Female (51) · Gonadal Disorders (51) · Neoplasms by Histologic Type (51) · Neoplasms, Connective Tissue (51) · Neoplasms, Connective and Soft Tissue (51) · Neoplasms, Fibroepithelial (51) · Neoplasms, Fibrous Tissue (51) · Neoplasms, Glandular and Epithelial (51) · Ovarian Diseases (51)
Paclitaxel (25) · Carboplatin (22) · Taxes (16) · Bevacizumab (10) · Cisplatin (8) · Disulfides (7) · Immunoglobulin G (7) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Docetaxel (3) · Platinum (3) · Topotecan (3) · Chemotherapy, Adjuvant (2) · Erlotinib Hydrochloride (2) · Etoposide (2) · Filgrastim (2)
Gynecologic Oncology Group (20) · National Cancer Institute (NCI) (14) · Fred Hutchinson Cancer Center (2) · GOG Foundation (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · University of Washington (2) · Celgene (1) · Cytran (1) · Masonic Cancer Center, University of Minnesota (1) · Medical Research Council (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1) · University of Chicago (1)
United States (46) · Canada (6) · Japan (4) · South Korea (3) · Norway (2) · Australia (1) · France (1) · Germany (1) · Singapore (1) · United Kingdom (1)
Peter G. Rose, MD (4) · Don Dizon (3) · Evanthia Galanis, MD (2) · Leona A. Holmberg, MD, PhD (2) · Mark Morgan (2) · Robert Kreitman, MD (2) · Amar Patel, MD (1) · Amit M Oza (1) · Anil K. Sood, MD (1) · Anil Sood (1) · Barbara Goff (1) · Bradley J Monk (1) · Bradley J. Monk, MD (1) · Bradley Monk (1) · Dan Veljovich, MD (1)
PMID 37185961, PMID 21941283, PMID 30633128, PMID 16110020, PMID 16368440, PMID 16394300, PMID 16412499, PMID 16515585, PMID 16631245, PMID 16959305, PMID 17264340, PMID 17906207, PMID 18430468, PMID 18640939, PMID 19451433, PMID 19596139, PMID 19671873, PMID 20837357, PMID 21529904, PMID 22119995, PMID 22204724, PMID 22204725, PMID 23219660, PMID 26487588, PMID 26933849, PMID 27394382, PMID 28341300, PMID 28438473, PMID 28453702, PMID 29550184, PMID 30309721, PMID 31002578, PMID 31216226, PMID 31708167, PMID 31722153, PMID 33485453, PMID 33610319, PMID 35144591, PMID 35759733, PMID 36252167, PMID 36608382, PMID 37407274
U10CA027469 (17), U10CA180868 (10), U10CA101165 (4), P50CA136393 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P30CA015083 (1), R01CA136547 (1), R01CA200507 (1), R21CA215662 (1), U10CA180821 (1), U10CA180830 (1), UG1CA189867 (1)